Idiopathic CD4+ T-lymphocytopenia (ICL) is a new disease entity characterized by CD4+ T-lymphocyte depletion without evidence of HIV infection. We report a 27-year-old ICL patient with a long history of multiple immune abnormalities. His CD4+ T-lymphocyte count started to decrease after generalized lymphadenopathy of an unknown cause at age 3. He satisfied the criteria for ICL at age 9, and the...

Although CD4+ T cells form a major subset of TCRab T cells, only a small number of TCRgd T cells express CD4. Factors contributing to the down-regulation of CD4+ TCRgd T cells have not been identi®ed. The CD5 molecule is expressed on most TCRgd T cells in the spleen, whereas only a few intestinal intraepithelial TCRgd T cells express this molecule in wild-type mice and TCRb mutant (b±/±) mice. ...

behcet disease (bd) is a systemic inflammatory disease of the unknown etiology. there is however, some evidence to suggest that immunological abnormalities are important in its pathogenesis, furthermore several t-cell abnormalities which may be quite relevant to autoimmune origin of the disease have been described. we report here our study of t-cell subsets, b and nk cells in 68 patients with b...

The progressive decline of CD4(+) T cells is a hallmark of disease progression in human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) infection. Whereas the acute phase of the infection is dominated by virus-mediated depletion of memory CD4(+) T cells, chronic infection is often associated with a progressive decline of total CD4(+) T cells, including the naïve subset. The...

Background: Ovarian cancer is the fifth leading cause of death from malignancy in women. CD4 +CD25+FoxP3+ regulatory T (Treg) cells are a subset of T lymphocytes with great inhibitory impact on immune response. Objectives: To investigate the percentage of CD4 +CD25+FoxP3+ regulatory T cells in the peripheral blood of the Iranian patients with epithelial ovarian cancer compared to healthy women ...

Background: Programmed cell death protein-1 (PD-1)/PD-L1 pathway is one of the immune checkpoint pathways involved in regulation of the immune responses and suppression of anti-tumor defense. PD-1/B7-H1-blocking antibodies improve immune responses such as cytotoxic activity of CD8+/CD4+T cells and also increase mortality of tumor cells; however their use is accompanied by adverse effects in pat...